Genocea Biosciences

$3.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.14 (4.07%) Today
-$0.08 (-2.23%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell GNCA and other stocks, options, ETFs, and crypto commission-free!

About GNCA

Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Read More Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

Employees
61
Headquarters
Cambridge, Massachusetts
Founded
2006
Market Cap
93.62M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
206.63K
High Today
$3.62
Low Today
$3.44
Open Price
$3.44
Volume
200.66K
52 Week High
$11.28
52 Week Low
$2.24

Collections

GNCA Earnings

-$0.66
-$0.46
-$0.25
-$0.05
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Oct 31, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.